142 related articles for article (PubMed ID: 14704818)
1. [Octreotide scintigraphy for the diagnosis of active Graves' ophthalmopathy].
Ardjomand N; Esche G; Fellner P; Lindner S; Panzitt M; Aigner R; Langmann A
Ophthalmologe; 2003 Dec; 100(12):1049-53. PubMed ID: 14704818
[TBL] [Abstract][Full Text] [Related]
2. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G
J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448
[TBL] [Abstract][Full Text] [Related]
3. Orbital gallium-67 scintigraphy in Graves' ophthalmopathy.
Konuk O; Atasever T; Unal M; Ayvaz G; Yetkin I; Cakir N; Arslan M; Hasanreisoglu B
Thyroid; 2002 Jul; 12(7):603-8. PubMed ID: 12193305
[TBL] [Abstract][Full Text] [Related]
4. Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy.
Gerding MN; van der Zant FM; van Royen EA; Koornneef L; Krenning EP; Wiersinga WM; Prummel MF
Clin Endocrinol (Oxf); 1999 Mar; 50(3):373-9. PubMed ID: 10435064
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatostatin analog 111In-octreotide.
Moncayo R; Baldissera I; Decristoforo C; Kendler D; Donnemiller E
Thyroid; 1997 Feb; 7(1):21-9. PubMed ID: 9086565
[TBL] [Abstract][Full Text] [Related]
6. Orbital gallium-67 scintigraphy in Graves' ophthalmopathy: a disease activity parameter that predicts the therapeutic response to immunosuppressive treatment.
Konuk O; Atasever T; Unal M; Ayvaz G; Yetkin I; Cakir N; Arslan M; Hasanreisoglu B
Thyroid; 2005 Apr; 15(4):358-63. PubMed ID: 15876160
[TBL] [Abstract][Full Text] [Related]
7. Recombinant thyrotropin-induced orbital uptake of [111In-diethylenetriamine-pentacetic acid-D-Phe1]octreotide in a patient with inactive Graves' ophthalmopathy.
Savastano S; Pivonello R; Acampa W; Salvatore M; Lombardi G; Colao A; Fenzi G
J Clin Endocrinol Metab; 2005 Apr; 90(4):2440-4. PubMed ID: 15687327
[TBL] [Abstract][Full Text] [Related]
8. Indium-111-pentetreotide scintigraphy in Graves' ophthalmopathy.
Kahaly G; Diaz M; Hahn K; Beyer J; Bockisch A
J Nucl Med; 1995 Apr; 36(4):550-4. PubMed ID: 7699440
[TBL] [Abstract][Full Text] [Related]
9. 111In-octreotide imaging in patients with long-standing Graves' ophthalmopathy.
Bohuslavizki KH; Oberwöhrmann S; Brenner W; Eberhardt JU; Mönig H; Clausen M; Sippel C; Wolf H; Epe B; Henze E
Nucl Med Commun; 1995 Nov; 16(11):912-6. PubMed ID: 8587756
[TBL] [Abstract][Full Text] [Related]
10. Graves' dermopathy: does octreotide scintigraphy predict the response to octreotide treatment?
Kuyvenhoven JP; van der Pijl JW; Goslings BM; Wiersinga WM
Thyroid; 1996 Oct; 6(5):385-9. PubMed ID: 8936660
[TBL] [Abstract][Full Text] [Related]
11. SPECT using 99mTc-DTPA for the assessment of disease activity in Graves' ophthalmopathy: a comparison with the results from MRI.
Galuska L; Leovey A; Szucs-Farkas Z; Garai I; Szabo J; Varga J; Nagy EV
Nucl Med Commun; 2002 Dec; 23(12):1211-6. PubMed ID: 12464787
[TBL] [Abstract][Full Text] [Related]
12. (99m)Tc-HYNIC-TOC scintigraphy in evaluation of active Graves' ophthalmopathy (GO).
Sun H; Jiang XF; Wang S; Chen HY; Sun J; Li PY; Ning G; Zhao YJ
Endocrine; 2007 Jun; 31(3):305-10. PubMed ID: 17906380
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin-receptor scintigraphy in Graves' disease: reproducibility and variance of orbital activity.
Förster GJ; Krummenauer F; Nickel O; Kahaly GJ
Cancer Biother Radiopharm; 2000 Oct; 15(5):517-25. PubMed ID: 11155823
[TBL] [Abstract][Full Text] [Related]
14. Indium-111 octreotide in Graves' disease and in the evaluation of active exophthalmos.
Mansi L; Rambaldi PF; Bizzarro A; Panza N; Di Martino S; De Bellis A; Del Vecchio E
Q J Nucl Med; 1995 Jun; 39(2):105-10. PubMed ID: 8574802
[TBL] [Abstract][Full Text] [Related]
15. Role of octreoscan and correlation with MR imaging in Graves' ophthalmopathy.
Kahaly G; Diaz M; Just M; Beyer J; Lieb W
Thyroid; 1995 Apr; 5(2):107-11. PubMed ID: 7647569
[TBL] [Abstract][Full Text] [Related]
16. 111In-octreotide in the evaluation of autoimmune thyroid diseases.
Mansi L; Rambaldi PF; Bizzarro A; Panza N; Del Vecchio E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):127-30. PubMed ID: 9002770
[TBL] [Abstract][Full Text] [Related]
17. Indium-111-pentetreotide in Graves' disease.
Kahaly G; Görges R; Diaz M; Hommel G; Bockisch A
J Nucl Med; 1998 Mar; 39(3):533-6. PubMed ID: 9529305
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease.
Krassas GE; Doumas A; Kaltsas T; Halkias A; Pontikides N
Thyroid; 1999 Jan; 9(1):47-52. PubMed ID: 10037076
[TBL] [Abstract][Full Text] [Related]
19. [111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity?
Postema PT; Krenning EP; Wijngaarde R; Kooy PP; Oei HY; van den Bosch WA; Reubi JC; Wiersinga WM; Hooijkaas H; van der Loos T
J Clin Endocrinol Metab; 1994 Dec; 79(6):1845-51. PubMed ID: 7989493
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor scintigraphy to predict the clinical evolution and therapeutic response of thyroid-associated ophthalmopathy.
Nocaudie M; Bailliez A; Itti E; Bauters C; Wemeau JL; Marchandise X
Eur J Nucl Med; 1999 May; 26(5):511-7. PubMed ID: 10382096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]